September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Article of the day, September 4th, suggested by the Immune Oncology Research Institute
Sep 4, 2024, 10:54

Article of the day, September 4th, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the day! Suggest by the Immune Oncology Research Institute.

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction

Authors: Bernhard Scheiner, Ciro Celsa, Thomas U. Marron, Matthias Pinter, Rohini Sharma, Yi-Hsiang Huang, Anjana Pillai, Andrea Napolitano, Caterina Vivaldi, Gianluca Masi, Marianna Silletta, Bruno Vincenzi, Dominik Bettinger, Robert Thimme, Arndt Vogel, Kornelius Schulze, Henning Wege, Peter R. Galle, Joong-Won Park, Masatoshi Kudo, Hong Jae Chon, Wei-Fan Hsu, Calogero Cammà, Franco Trevisani, Edoardo G. Giannini, Alessio Cortellini and David James Pinato.

Article of the day, September 4th, suggested by the Immune Oncology Research Institute

Author Affilitions: Hammersmith Hospital ,Lorenzo Nibid,Humanitas Research Hospital ,et al.

Source: Immune Oncology Research Institute/LinkedIn

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.

Other posts featuring Immune Oncology Research Institute on OncoDaily.